0.1480.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:00Valuation
Current ValuationThe current P/E ratio is -1.01, above the reasonable range, cheaper than 10.34% of the time in the past 1 years, and the industry ranks 36/53, the industry Median 6.94.
-1.01xP/E
HK$0.15Stock price
HK$-0.15Earnings per share
-1.01xP/E
Stock priceHK$0.15Earnings per shareHK$-0.15
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.75x
- Typical range
- -4.02x–-1.06x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.94x
010203040
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.94x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
06887HKSUNSHINE PHARMA | -63.90x | -- | HK$20.96B |
02630HKVIGONVITA-B | -34.60x | -- | HK$12.14B |
09637HKALEBUND-B | -8.63x | 48.51% | HK$6.99B |
00570HKTRAD CHI MED | -4.80x | 223.71% | HK$5.59B |
02575HKXUANZHUBIO-B | -18.10x | -- | HK$4.37B |
01477HKOCUMENSION-B | -26.66x | 52.42% | HK$3.85B |
01349HKFUDANZHANGJIANG | -20.24x | -- | HK$2.43B |
02552HKHUA MEDICINE-B | -17.62x | 104.78% | HK$2.19B |
02652HKCF PHARMTECH | -253.38x | -- | HK$1.98B |
06622HKZHAOKE OPHTH-B | -4.66x | -- | HK$1.15B |
01652HKFUSEN PHARM | -224.00x | -- | HK$598.83M |
01011HKNT PHARMA | -11.72x | -- | HK$371.89M |
01643HKMODERN CHI MED | -7.01x | -- | HK$338.40M |
00575HKREGENT PACIFIC | -15.16x | -- | HK$231.99M |
08329HKNEP INTERLONG | -3.43x | -- | HK$208.07M |
01312HKKONTA CHINA | -0.79x | -- | HK$167.66M |
00455HKTIANDA PHARMA | -2.27x | -- | HK$156.95M |
00858HKEXTRAWELL PHAR | -0.16x | -- | HK$153.70M |
01498HKPURAPHARM | -4.26x | -- | HK$117.90M |
01889HKSANAI HEALTH GP | -1.01x | -- | HK$22.63M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
